Clearmind Medicine dosed two additional participants in the fourth cohort of its Phase I/IIa trial for CMND-100, reaching 20 total participants treated.
Key takeaways
Two participants dosed in fourth cohort at 160 mg, following positive DSMB recommendation.
Total participants treated across all cohorts now 20, with no serious adverse events reported.
Trial is a multinational, multicenter study evaluating CMND-100 for moderate to severe AUD.
Consistent safety data reinforces confidence in CMND-100 as a non-hallucinogenic treatment option.